Triamcinolone injection improves visual acuity in uveitic macular edema

Source/Disclosures

Source:

Yeh S, et al. Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: an integrated analysis of two clinical trials. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Disclosures:
Yeh claims to be a consultant for Adverum, Allergan, Bausch Health, Clearside Biomedical and Regenxbio.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

DENVER — Two phase 3 studies have shown that suprachoroidal injections of triamcinolone acetonide lead to significant improvement in visual acuity.

Steven Yeh, MD, of the Truhlsen Eye Institute, University of Nebraska Medical Center, said that at 4 weeks, patients with macular edema associated with uveitis had gained up to 10 letters of improvement and at 24 weeks, 14 letters.

Briana R. Cross